bioRxiv Subject Collection: Pharmacology And Toxicology
https://biorxiv.org
This feed contains articles for bioRxiv Subject Collection "Pharmacology And Toxicology"
bioRxivbioRxivhttps://www.biorxiv.org/sites/default/files/bioRxiv_article.jpg
https://www.biorxiv.org
<![CDATA[
Identification of co-expressed gene sets for major molecular initiating events in rodent liver carcinogenesis using wild type and knock out rats
]]>
https://www.biorxiv.org/content/10.64898/2026.09.15.751815v1?rss=1
2026-09-21doi:10.64898/2026.09.15.751815Cold Spring Harbor Laboratory2026-09-21
<![CDATA[
High-throughput phenotypic profiling of insecticide responses in mosquito larvae
]]>
https://www.biorxiv.org/content/10.64898/2026.09.16.752149v1?rss=1
2026-09-21doi:10.64898/2026.09.16.752149Cold Spring Harbor Laboratory2026-09-21
<![CDATA[
EFFECTS OF SUBCHRONIC EXPOSURE TO POLYSTYRENE NANOPLASTICS ON THE MOUSE INTESTINE
]]>
https://www.biorxiv.org/content/10.64898/2026.09.15.751754v1?rss=1
2026-09-21doi:10.64898/2026.09.15.751754Cold Spring Harbor Laboratory2026-09-21
<![CDATA[
A non-retinoid triazolopyrimidine RBP4 antagonist for the treatment of Stargardt disease
]]>
https://www.biorxiv.org/content/10.64898/2026.09.14.751502v1?rss=1
2026-09-21doi:10.64898/2026.09.14.751502Cold Spring Harbor Laboratory2026-09-21
<![CDATA[
ACAN regulates VSMC mitochondrial homeostasis through the YAP1/TAZ pathway and contributes to the onset and progression of aortic dissection
]]>
https://www.biorxiv.org/content/10.64898/2026.09.14.751622v1?rss=1
2026-09-21doi:10.64898/2026.09.14.751622Cold Spring Harbor Laboratory2026-09-21
<![CDATA[
Hepatic Xanthine Oxidoreductase Sustains Antithrombotic Nitric Oxide Signalling Through the Nitrate-Nitrite-Nitric Oxide Pathway
]]>
https://www.biorxiv.org/content/10.64898/2026.09.13.751308v1?rss=1
2026-09-19doi:10.64898/2026.09.13.751308Cold Spring Harbor Laboratory2026-09-19
<![CDATA[
The COVID-19 RNA vaccine SpikevaxTM transfects human umbilical endothelial cells and induces Spike protein production, inflammation and leukocyte adhesion
]]>
https://www.biorxiv.org/content/10.64898/2026.09.15.751712v1?rss=1
2026-09-18doi:10.64898/2026.09.15.751712Cold Spring Harbor Laboratory2026-09-18
<![CDATA[
Cinnamaldehyde interacts with the local anesthetic pocket of the NaV 1.5 channel
]]>
https://www.biorxiv.org/content/10.64898/2026.09.13.751249v1?rss=1
2026-09-18doi:10.64898/2026.09.13.751249Cold Spring Harbor Laboratory2026-09-18
<![CDATA[
Exposure to a mixture of long-chain PFAS disrupts ovarian follicle development, ovulation, and luteinization in female mice
]]>
https://www.biorxiv.org/content/10.64898/2026.09.12.750977v1?rss=1
2026-09-18doi:10.64898/2026.09.12.750977Cold Spring Harbor Laboratory2026-09-18
<![CDATA[
Multispecies translational evaluation of an NMDA receptor modulator reveals analgesic, autonomic-stabilizing, and stress mitigating effects without evidence of abuse liability
]]>
https://www.biorxiv.org/content/10.64898/2026.09.14.751462v1?rss=1
2026-09-18doi:10.64898/2026.09.14.751462Cold Spring Harbor Laboratory2026-09-18
<![CDATA[
Genetically-encoded discovery and development of peptide-macrocycle imaging agents for PD-L1
]]>
https://www.biorxiv.org/content/10.64898/2026.09.11.750985v1?rss=1
10,000 variants in ''focused'' phage-display libraries, we optimized these macrocycles to achieve single-digit-nanomolar potency in protein- and cell-based assays. En route to this optimization, the activity of 216 synthetic macrocycles towards PD-L1 was measured in five distinct assays; two leads have been evaluated by imaging in tumor xenografts in mice, and the X-ray structure of one advanced lead in complex with PD-L1 has been determined at 2.78 [A] resolution. This publication demonstrates the development potential of PD-L1-targeting macrocycles that do not require extensive incorporation of ncAAs and the democratization of discovery by mapping the optimization path to single-digit-nanomolar assets for targeted radiopharmaceuticals via canonical phage-display technology.
]]>2026-09-18doi:10.64898/2026.09.11.750985Cold Spring Harbor Laboratory2026-09-18
<![CDATA[
Hepatotoxicity assessment of antimalarial compounds from microorganisms using a liver organ-on-a-chip system
]]>
https://www.biorxiv.org/content/10.64898/2026.09.10.750749v1?rss=1
50 {micro}M, offering a superior safety profile with a selectivity index > 23.7. Functional assessment of HepG2 OOCs showed that NATPP0650 and NATPP0437 markedly suppressed albumin production at 10 and 50 {micro}M, whereas NATPP0604 showed minimal inhibition. However, long-term (7 days) toxicity testing on the OOC model revealed a critical finding: NATPP0604 exerted delayed hepatotoxic effects that were undetectable in the 24-h study, as evidenced by partial reductions in cell viability at 10 and 50 {micro}M and decreased albumin production across all tested concentrations. These findings demonstrate the therapeutic safety potential of NATPP0604 for further development as an antimalarial drug and underscore the importance of the long-term OOC data in establishing accurate safety margins for future clinical trials.
]]>2026-09-17doi:10.64898/2026.09.10.750749Cold Spring Harbor Laboratory2026-09-17
<![CDATA[
Acute head shaking precedes chronic corpus callosum deficits during repeated cocaine exposure in common marmosets
]]>
https://www.biorxiv.org/content/10.64898/2026.09.11.749290v1?rss=1
2026-09-16doi:10.64898/2026.09.11.749290Cold Spring Harbor Laboratory2026-09-16
<![CDATA[
Non-invasive quantification of hepatic necrosis from circulating alanine aminotransferase kinetics in acetaminophen-treated mice in vivo
]]>
https://www.biorxiv.org/content/10.64898/2026.09.11.750627v1?rss=1
2026-09-16doi:10.64898/2026.09.11.750627Cold Spring Harbor Laboratory2026-09-16
<![CDATA[
Replacing In Vivo Experiments for PK/PD Target Determination Through In Vitro Time-Kill Experiments and PK/PD Modelling Incorporating Inter-strain Variability: Application to Meropenem Against Pseudomonas aeruginosa
]]>
https://www.biorxiv.org/content/10.64898/2026.09.10.750598v1?rss=1
MIC) were characterized using nonlinear mixed-effects Imax models. Results. The PK/PD index showing the strongest correlation with meropenem efficacy at 24 h was %fT>MIC (R2 = 0.989), compared with fAUC/MIC (R2 = 0.373) and fCmax/MIC (R2 = 0.284). These findings are consistent with previous studies using murine thigh infection models. The %fT>MIC target required to achieve a 2-log CFU reduction was estimated at 44%, with substantial inter-strain variability (10th and 90th percentiles: 27% and 71%, respectively). Conclusions. Using meropenem against P. aeruginosa as a proof of concept, we demonstrate that in vitro time-kill experiments combined with pharmacometric modelling can identify the same PK/PD efficacy targets as animal infection models. Moreover, performing experiments on a large panel of clinical isolates enables the quantification of inter-strain variability in PK/PD targets, providing information that may improve their translation to clinical dosing optimization.
]]>2026-09-15doi:10.64898/2026.09.10.750598Cold Spring Harbor Laboratory2026-09-15
<![CDATA[
Protective effects of heat shock protein 70 induction against global warming by using oriental bezoar and ginseng
]]>
https://www.biorxiv.org/content/10.64898/2026.09.08.750282v1?rss=1
2026-09-15doi:10.64898/2026.09.08.750282Cold Spring Harbor Laboratory2026-09-15
<![CDATA[
Comparative effects of central and peripheral PDE10A inhibition on weight gain following semaglutide cessation in diet-induced obese mice
]]>
https://www.biorxiv.org/content/10.64898/2026.09.07.749896v1?rss=1
2026-09-14doi:10.64898/2026.09.07.749896Cold Spring Harbor Laboratory2026-09-14
<![CDATA[
Physicochemical compatibility and stability of urapidil-propofol admixtures during simulated Y-site Administration
]]>
https://www.biorxiv.org/content/10.64898/2026.09.07.749885v1?rss=1
95%, MDD was < 500 nm, and PDI was < 0.2. Urapidil proportion in NS was significantly negatively correlated with the zeta potential. PFAT5 was > 0.05% after 2-8 h. In contrast, in GS at a 1:2 ratio, PFAT5 remained < 0.05%, which increased slightly in the 1:1 group at 8 h. PFAT5 stabilized in the high-propofol group (10:1) under all conditions. Conclusions: The chemical compatibility of the admixture was acceptable after 12 h of storage. However, physical compatibility was influenced by the mixing ratio, diluent type, and storage time. For clinical Y-site co-administration, a 10:1 mixing ratio or dilution in 5% GS is recommended. Enhanced proportions must be mixed with NS, while continuous infusion time must be < 2 h to mitigate fat embolism risk.
]]>2026-09-14doi:10.64898/2026.09.07.749885Cold Spring Harbor Laboratory2026-09-14
<![CDATA[
Integrated pharmacological and structural profiling reveals CB1 residue interaction patterns associated with synthetic cannabinoid receptor agonist efficacy
]]>
https://www.biorxiv.org/content/10.64898/2026.09.08.748791v1?rss=1
2026-09-14doi:10.64898/2026.09.08.748791Cold Spring Harbor Laboratory2026-09-14
<![CDATA[
Blockade of Kv3.1 by MK-801, a PCP-Derivative NMDA Receptor Inhibitor: Implications for Models of Schizophrenia
]]>
https://www.biorxiv.org/content/10.64898/2026.09.06.749750v1?rss=1
2026-09-13doi:10.64898/2026.09.06.749750Cold Spring Harbor Laboratory2026-09-13
<![CDATA[
Free fatty acid 2 receptor regulates the NADPH oxidase activity induced by formyl peptide receptor specific agonists
]]>
https://www.biorxiv.org/content/10.64898/2026.09.05.749594v1?rss=1
2026-09-11doi:10.64898/2026.09.05.749594Cold Spring Harbor Laboratory2026-09-11
<![CDATA[
Genotoxicity and 90-day oral toxicity of a monk fruit (Siraitia grosvenorii) mogroside preparation (>=95% mogrosides) produced by microbial fermentation
]]>
https://www.biorxiv.org/content/10.64898/2026.09.04.749478v1?rss=1
2026-09-11doi:10.64898/2026.09.04.749478=95% mogrosides) produced by microbial fermentation]]>Cold Spring Harbor Laboratory2026-09-11
<![CDATA[
Aryl Hydrocarbon Receptor (Ahr) Pathway Drives TBBPA Induced Cartilage Development Defects.
]]>
https://www.biorxiv.org/content/10.64898/2026.09.07.749921v1?rss=1
2026-09-11doi:10.64898/2026.09.07.749921Cold Spring Harbor Laboratory2026-09-11
<![CDATA[
Gain- and loss-of-function mutations cause perinatal lethality in mouse models of Birk-Barel syndrome
]]>
https://www.biorxiv.org/content/10.64898/2026.09.08.750008v1?rss=1
2026-09-10doi:10.64898/2026.09.08.750008Cold Spring Harbor Laboratory2026-09-10
<![CDATA[
A Temporal Reliability and Sustainability Score Framework for Ranking Heart Rate Variability Metrics During Pharmacological Autonomic Blockade in Rats
]]>
https://www.biorxiv.org/content/10.64898/2026.09.04.748642v1?rss=1
2026-09-09doi:10.64898/2026.09.04.748642Cold Spring Harbor Laboratory2026-09-09
<![CDATA[
A novel workflow integrating whole-body PET microdosing data and therapeutic-dose pharmacokinetics across species to inform first-in-human dose selection
]]>
https://www.biorxiv.org/content/10.64898/2026.09.03.748870v1?rss=1
2026-09-08doi:10.64898/2026.09.03.748870Cold Spring Harbor Laboratory2026-09-08
<![CDATA[
Direct-to-Biology Strategy Accelerates CRBN-Targeting Molecular Glue Degrader Discovery
]]>
https://www.biorxiv.org/content/10.64898/2026.09.02.747152v1?rss=1
2026-09-08doi:10.64898/2026.09.02.747152Cold Spring Harbor Laboratory2026-09-08
<![CDATA[
Structure-Guided Design of C5aR1-Selective Peptide Agonists
]]>
https://www.biorxiv.org/content/10.64898/2026.09.02.746116v1?rss=1
2026-09-08doi:10.64898/2026.09.02.746116Cold Spring Harbor Laboratory2026-09-08
<![CDATA[
mRNA-LNP therapy restores systemic nucleoside imbalance in a mitochon-drial DNA depletion syndrome
]]>
https://www.biorxiv.org/content/10.64898/2026.09.08.750057v1?rss=1
2026-09-08doi:10.64898/2026.09.08.750057Cold Spring Harbor Laboratory2026-09-08
<![CDATA[
Beyond hazard identification: Discovering mechanisms of action from a ToxCast chemical screen in zebrafish
]]>
https://www.biorxiv.org/content/10.64898/2026.09.01.748647v1?rss=1
2026-09-05doi:10.64898/2026.09.01.748647Cold Spring Harbor Laboratory2026-09-05